Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Q3 2022 vs. Q2 2022
How the institutions holding Cidara Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 46 | 42 | −4 |
| Shares | 27.2M | 27.1M | −142.6K (−0.5%) |
| Value | $13.3M | $17.1M | +$3.77M (+28.3%) |
New holders (5)
Institutions that held Cidara Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Monashee Investment Management LLC | 369,099 | $232.0K | 0.09% |
| Tocqueville Asset Management L.P. | 104,000 | $65.0K | 0.00% |
| Prudential Financial Inc | 54,000 | $34.0K | 0.00% |
| Two Sigma Securities, LLC | 41,819 | $26.0K | 0.00% |
| Raymond James & Associates | 11,672 | $7.00K | 0.00% |
Sold out (9)
Institutions that held Cidara Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Stonepine Capital Management, LLC | 208,443 | $102.0K |
| Citadel Advisors LLC | 57,350 | $28.0K |
| Barclays PLC | 44,185 | $22.0K |
| Jane Street Group, LLC | 40,625 | $20.0K |
| Bank of America Corp | 25,157 | $12.0K |
| Ground Swell Capital, LLC | 11,397 | $6.00K |
| Shufro Rose & Co LLC | 10,413 | $5.00K |
| HRT Financial LP | 10,208 | $4.00K |
| UBS Group AG | 11 | $0 |